Drug-Resistant Model Services

Drug resistance remains the single greatest hurdle in oncology, driving the urgent need for translatable preclinical models that mimic clinical treatment failure. Alfa Cytology provides a comprehensive ecosystem of Drug Resistance Models, ranging from patient-derived avatars to engineered cell lines. By integrating PDX, Patient-Derived Organoids (PDO), and Induced Resistance Platforms, we empower partners to dissect complex resistance mechanisms and validate effective second-line or combination therapeutic strategies.

Strategic Preclinical Framework for Resistance Research

We provide a multidimensional "Roadmap" to help researchers select the optimal platform based on clinical history and molecular drivers:

Clinical Avatars: Patient-Derived Xenografts (PDX)

Utilizing tissues from patients who failed the Standard-of-Care (SoC). Ideal for Biomarker Discovery and evaluating efficacy against heterogeneous clinical resistance (e.g., KRAS-driven Cetuximab resistance).

Evolutionary Modeling: Induced Resistance Platforms

Replicating tumor progression through chronic in vivo/in vitro drug exposure. Perfect for studying Acquired Resistance and Bypass Signaling emergence under therapeutic pressure.

Precision Isolation: Engineered Isogenic Models

Using CRISPR-Cas9 to introduce secondary mutations into sensitive genetic backgrounds. Essential for target validation and structure-activity relationship (SAR) studies in a controlled environment.

Efficiency Pipeline: The PDO-to-PDX Bridge

High-throughput screening in Patient-Derived Organoids (PDO) followed by validation in paired PDX models. This synergizes speed with in vivo fidelity for complex combination regimens.

Advanced Applications in Drug Resistance

Alfa Cytology platforms integrate clinically relevant resistance models for oncology drug discovery.

Patient-Derived Xenografts from Post-Resistance Patients

Retain tumor heterogeneity and clinical resistance phenotypes; ideal for second-line therapy validation.

Induced Resistance via Chronic Drug Exposure

Recapitulate acquired resistance and drug-tolerant persister (DTP) cells through long-term in vivo or in vitro selection.

Engineered Isogenic Models with Defined Mutations

Use CRISPR-Cas9 to introduce secondary mutations for target validation and SAR studies.

Drug-Tolerant Persister (DTP) Models

Capture quiescent resistant subpopulations following cytotoxic therapy; enable evaluation of eradicative strategies.

Our Services

Validated Drug Resistance Model Biobank

Alfa Cytology maintains an extensive, character-verified repository of drug-resistant models mirroring current clinical patterns. Every model is validated through NGS profiling, STR identification, and SoC (Standard-of-Care) benchmarking to ensure a stable and reproducible resistant phenotype.

Explore our comprehensive list of available models below:

Why Choose Alfa Cytology?

Translational Excellence

Precision Engineering

Comprehensive Coverage

Regulatory-Ready

Contact Us for Tailored Resistance Solutions

Alfa Cytology is committed to providing the most advanced Drug Resistance Models to overcome the challenges of modern oncology. Whether you are investigating bypass signaling or validating complex combination regimens, our expert team is ready to support your project. Contact us today to discuss how our resistance platforms can be tailored to meet your research milestones and accelerate your path to the clinic.

For research use only. Not intended for any clinical use.